NDA 208294 · Astrazeneca
Bevespi Aerosphere
Formoterol Fumarate, Glycopyrrolate · Inhalation
Last checked: Nov 19, 2026Latest source record: Nov 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 25, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
514
215 Phase 3, 21 recruiting
FAERS reports
1,968
799 serious, 233 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 24, 2023.
BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] . BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.1 , 5.2 )
Mechanism: BEVESPI AEROSPHERE BEVESPI AEROSPHERE contains both glycopyrrolate and formoterol fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD. Glycopyrrolate Glycopyrrolate is a long-acting antimuscarinic agent which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BEVESPI AEROSPHERE · FORMOTEROL FUMARATE 0.0048MG/INH; GLYCOPYRROLATE 0.0090MG/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Formoterol" as an intervention, any sponsor and status, largest first.
- A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01444430 · 12,460 participants · Start Dec 2011 · Primary completion Oct 2015
Drug: Symbicort pMDI; budesonide pMDI · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 340 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Local Phase 4 Pan-European SMART StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463866 · 8,424 participants · Start Mar 2007
Drug: Budesonide/formoterol · For: Asthma
Sites: Aalst, Belgium; Aarschot, Belgium; Aatrijken, Belgium · 817 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea378
- death207
- cough164
- device malfunction161
- chronic obstructive pulmonary disease156
- off label use152
- wrong technique in device usage process150
- device issue145
- product dose omission issue138
- drug ineffective124
- intentional product misuse118
- wrong technique in product usage process113
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 8 |
| 2017 | 343 |
| 2018 | 264 |
| 2019 | 244 |
| 2020 | 231 |
| 2021 | 172 |
| 2022 | 134 |
| 2023 | 170 |
| 2024 | 188 |
| 2025 | 119 |
| 2026 | 91 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bevespi Aerosphere (Glycopyrrolate/Formoterol Fum)
2024 spending
$65.5M
Beneficiaries
31,184
125,109 claims
Per beneficiary
$2,102
$38.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $72,965,723 |
| 2021 | $77,583,374 |
| 2022 | $69,437,411 |
| 2023 | $66,814,262 |
| 2024 | $65,535,900 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis.
Rayner DG, Ferri DM, Guyatt GH, et al. · JAMA 2025 · Comparative Study, Research Support, N.I.H., Extramural
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hatter L, Holliday M, Oldfield K, et al. · Lancet 2025 · Multicenter Study, Randomized Controlled Trial
- Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
Beasley R, Harrison T, Peterson S, et al. · JAMA Netw Open 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
Bateman ED, Reddel HK, O'Byrne PM, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.